Display options
Cite
Kimby E, Mellstedt H. Chlorambucil/Prednisone versus CHOP in Symptomatic Chronic Lymphocytic Leukemias of B-Cell type. A Randomized Trial. Leuk Lymphoma. 1991;5:93-6doi: 10.3109/10428199109103386.
Kimby, E., & Mellstedt, H. (1991). Chlorambucil/Prednisone versus CHOP in Symptomatic Chronic Lymphocytic Leukemias of B-Cell type. A Randomized Trial. Leukemia & lymphoma, 593-6. https://doi.org/10.3109/10428199109103386
Kimby, E, and Mellstedt, H. "Chlorambucil/Prednisone versus CHOP in Symptomatic Chronic Lymphocytic Leukemias of B-Cell type. A Randomized Trial." Leukemia & lymphoma vol. 5 (1991): 93-6. doi: https://doi.org/10.3109/10428199109103386
Kimby E, Mellstedt H. Chlorambucil/Prednisone versus CHOP in Symptomatic Chronic Lymphocytic Leukemias of B-Cell type. A Randomized Trial. Leuk Lymphoma. 1991;5:93-6. doi: 10.3109/10428199109103386. PMID: 27463487.
Copy Download .nbib Format: NLM
Share it on

Leuk Lymphoma. 1991;5:93-6. doi: 10.3109/10428199109103386.

Chlorambucil/Prednisone versus CHOP in Symptomatic Chronic Lymphocytic Leukemias of B-Cell type. A Randomized Trial.

Leukemia & lymphoma

E Kimby, H Mellstedt

Affiliations

  1. a Lymphoma Group of Central Sweden (LGCS), Dept. of Medicine, Division of Hematology Danderyd Hospital, Stockholm, Sweden.
  2. b Lymphoma Group of Central Sweden (LGCS), Dept. of Oncology (Radiumhemmet), Karolinska Hospital, Stockholm, Sweden.

PMID: 27463487 DOI: 10.3109/10428199109103386

Abstract

The therapeutic efficacy of intensive chemotherapy (CHOP) versus palliative low-dose therapy (chlorambucil/prednisone, ChP) was studied in a randomized trial including 258 previously untreated patients with asymptomatic low-grade non-Hodgkin lymphomas stage III and IV. The patients were stratified according to histological subgroup (the Kiel classification). 113 patients with chronic lymphocytic leukemia (CLL), including B-CLL and leukemic lymphoplasmacytoid immunocytoma (1C), were evaluated separately and presented here. The therapeutic goal was to achieve an asymptomatic state in the ChP group, while in patients allocated to CHOP the intention was to reach complete remission. Thus, in the CHOP group a higher response rate was noted than in the ChP group but no statistically significant difference in overall survival was seen. The results do not support the use of intensive chemotherapy as first line therapy in symptomatic CLL.

Keywords: B-CLL; CHOP; chlorambucil/prednisone; symptomatic CLL

Publication Types